A biopharma company required expert due diligence for a potential transaction with a clinical stage biotech focusing in inflammation and fibrosis. Alacrita was commissioned to provide an assessment of the target company's lead clinical candidate, a first-in-class monoclonal antibody in development for multiple autoimmune and liver diseases.
Alacrita reviewed all relevant company information, including preclinical publications, pharmacology and toxicology reports, clinical trial documentation and plans, CMC strategy, regulatory correspondence and IP. Together with an evaluation of the competitive landscape and market opportunity, our expert team quantified the commercial and technical risks associated with the investment. This was presented to the client as a detailed report summarizing the marketable advantages of the lead molecule with important risk areas flagged and ranked. Our client proceeded with the investment and within two years, the company was listed on NASDAQ.Back